Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for Which Time to Disease Progression Is the Primary Endpoint

2000 ◽  
Vol 21 (4) ◽  
pp. 343-359 ◽  
Author(s):  
Rosemarie Mick ◽  
John J Crowley ◽  
Raymond J Carroll
Keyword(s):  
Clinical Trial ◽  
Disease Progression ◽  
Phase Ii ◽  
Primary Endpoint ◽  
Anticancer Agents ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Phase Ii Clinical Trial

scholarly journals A two‐stage phase II clinical trial design with nested criteria for early stopping and efficacy

2019 ◽  
Vol 18 (6) ◽  
pp. 700-713
Author(s):  
Michelle DeVeaux ◽  
Michael Kane ◽  
Wei Wei ◽  
Daniel Zelterman
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Phase Ii Clinical Trial ◽  
Early Stopping ◽  
Two Stage

A Bayesian-frequentist two-stage single-arm phase II clinical trial design

2012 ◽  
Vol 31 (19) ◽  
pp. 2055-2067 ◽  
Author(s):  
Gaohong Dong ◽  
Weichung Joe Shih ◽  
Dirk Moore ◽  
Hui Quan ◽  
Stephen Marcella
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Phase Ii Clinical Trial ◽  
Two Stage

Bayesian optimal phase II clinical trial design with time‐to‐event endpoint

2020 ◽  
Vol 19 (6) ◽  
pp. 776-786 ◽  
Author(s):  
Heng Zhou ◽  
Cong Chen ◽  
Linda Sun ◽  
Ying Yuan
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Phase Ii Clinical Trial ◽  
Time To Event
Sign in / Sign up

Export Citation Format

Share Document